Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A 5-year update from the CheckMate 9ER trial confirms that cabozantinib plus nivolumab consistently outperforms sunitinib in advanced renal cell carcinoma (aRCC) patients with bone metastases. The combo nearly doubled median overall survival (34.8 vs. 20.7 months) and cut the risk of disease progression by more than half. Importantly, the benefit held up even in patients with additional liver and/or lung metastases.
Five years of follow-up data from the phase 3 CheckMate 9ER trial continue to make a strong case for cabozantinib plus nivolumab (C+N) as a first-line treatment for advanced renal cell carcinoma (aRCC) — even in patients with bone metastases, who typically face a tougher prognosis. Presented at IKCS: North America 2026, the updated exploratory analysis compared outcomes in 154 patients with bone metastases at baseline versus 497 without.
The results showed C+N consistently outperformed sunitinib across all key metrics. Patients with bone metastases saw a median overall survival of 34.8 months on C+N vs. 20.7 months on sunitinib, and the benefit persisted even in the most complex subgroup — those with simultaneous bone, liver, and lung metastases (median OS: 20.9 vs. 12.6 months).
By the Numbers:
Why it matters: Bone metastases in aRCC signal a poor prognosis, and clinicians often face uncertainty about optimal treatment in this subgroup. These 5-year data provide reassurance that C+N delivers durable, meaningful benefits regardless of metastatic burden — helping guide treatment decisions for some of the most challenging patients.